Clinical Trial Update: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ribociclib in combination with endocrine therapy of physician's choice for locoregional recurrent, hormone receptor-positive, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Locoregional Recurrence of Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Oana Danciu | Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer | Phase 2 | Status: RECRUITING